We suggest that the perioperative assessment of coagulation status should be implemented through thromboelastometry and thromboelastography in patients with cirrhosis and significant coagulopathy, as well as in a hypercoagulability state with tranexamic acid administration. (2C)

In haemophilia patients, pharmacokinetic-guided treatment should be implemented over real body weight-guided treatment to assure an optimal perioperative achievement of the prespecified coagulation factor range (2B)

We recommend that patients with haemophilia, von Willebrand disease and factor X deficiency should be managed with a coordinated, multidisciplinary approach to their care. (1C)

We recommend using frailty testing as an effective tool for predicting postoperative outcomes, especially for assessing the risk of delirium. (1C)

We recommend using the Clinical Frailty Scale if the preoperative anaesthesia physical examination reveals the presence of a frailty phenotype. We should ask for evaluation by a geriatrician to improve the cognitive, nutritional and comorbidity status by delaying surgery (time-sensitive or elective procedures) when possible. (1C)

We recommend using the Clinical Frailty Scale because of its high feasibility and predictive values. (1C)

The role of prehabilitation should be established in noncardiac surgery patients.(2B)

Nutritional support before surgery should be considered in noncardiac surgery patients.(2C)

We do not recommend routine admission to the ICU for patients with stable cardiac diseases undergoing elective major surgery. Selective access to the ICU in this subset of patients following a multidisciplinary evaluation of the risk-to-benefit ratio might be more appropriate. (1C)

When a GLP-1 agonist is prescribed as a weekly injection and considering the long half-life of GLP-1 agonists, we recommend pausing GLP-1 agonists at least 1 week before a scheduled procedure requiring sedation/anaesthesia. If these drugs are given for obesity, then 2 weeks (three half-lives) are recommended. (CPS)